Mesothelioma & Asbestos

The number of people diagnosed with asbestos caused diseases in the U.S. continues to increase. Experts believe 60,000 mesothelioma deaths will occur between 2010 and 2030.

Industrial Accidents

Work related injuries harm up to 14 million people annually, with harms including traumatic brain injuries, spinal injuries, amputations, burns, and electrocutions. Around 20,000 to 60,000 workers die each year from accidents, toxins, and violence at their jobs.

Product Defects

Millions of consumers and workers are injured each year because of defective products. Defects can occur when a product is designed poorly, when a product is manufactured in a manner that differs from the intended design, or when the product does not contain proper warnings or instructions. Defects can occur in automobiles, pharmaceuticals, medical devices, construction equipment, toys, and other goods.

Nursing Home Abuse

Between 1.5 and 2 million elderly reside in nursing home facilities, with studies revealing that 44% have suffered some form of abuse. Many believe the actual number of residents suffering abuse is much higher. Neglect and abuse may result in serious emotional, physical, and financial harm

Our Experience

Paul & Hanley’s legal team has produced some of the most notable verdicts and highest settlements in the United States. Over 500 of our clients have each obtained in excess of 1 million dollars. Over 250 have recovered multi-million dollar recoveries.

< Back Pause Next >

Home ›

AZD 2171

Cediranib (tentative trade name Recentin), also known as AZD 2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.  It is being developed by AstraZeneca as a possible chemotherapeutic agent for oral administration.

As of 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer and colorectal cancer in adults, as well as tumors of the central nervous system in children.

On February 27th, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.  However, there are still 23 ongoing clinical trials listed in the cancer.gov trial database using this drug.  And one of those trials is using AZD2171 for mesothelioma.

Free Case Evaluation Form (800) 281-9804

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Free Case Evaluation Form (800) 281-9804